R^1 is  ,

wherein:

R^3 is a benzyl group optionally substituted by a methoxy group,

R^4 is a hydrogen atom, or

R^3 and R^4 together are a -CO-CH_2-O- bridge, the carbonyl group of the bridge being bound to the nitrogen; and

R^2 is  or  ,

wherein:

R^5 is a dimethylamino, methoxy, or butoxy group,

X is a nitrogen or a carbon atom, and

R^6 is a methoxyphenyl group, if X is nitrogen, or is an anellated phenyl ring also linked to X, if X is carbon,

or acid addition salt thereof.--

--2. (Amended) The compound of formula 1 according to claim 1, wherein:

R^1 is  or  ; and

R^2 is  ,  ,  ,  , or  .--

--3. (Amended) The compound of formula **1** according to claim 1, wherein:

R^1 is  or  ; and

R^2 is  ,  , or  .--

--4. (Amended) The compound of formula **1** according to claim 1, wherein:

R^1 is  ,

wherein R^3 and R^4 together are a -CO-CH_2-O- bridge, the carbonyl group of the bridge being bound to the nitrogen, and

R^2 is  or  ,

wherein:

R^5 is a dimethylamino, methoxy, or butoxy group,

X is a nitrogen or a carbon atom, and

R^6 is a methoxyphenyl group, if X is nitrogen, or an anellated phenyl ring also linked to X, if X is carbon.--

--5. (Amended) The compound of formula **1** according to claim 1, wherein:

R^1 is  ; and

R^2 is  ,  ,  , or  .--

A1 Cont

--6. (Amended) The compound of formula **1** according to claim 1, wherein:

R^1 is  ,

wherein:

R^3 is a benzyl group optionally substituted by methoxy, and

R^4 is a hydrogen atom; and

R^2 is  ,

wherein:

X is a nitrogen or a carbon atom,

R^6 is a methoxyphenyl group, if X is nitrogen, or an anellated phenyl ring also linked to X, if X is carbon.--

A2

--8. (Amended) 1-[3-(4-methoxybenzylamino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol, or an acid addition salt thereof.--

--9. (Amended) 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-[3-(4-*N*,*N*-dimethylaminophenyl)-2-methyl-2-propylamino]ethanol, or an acid addition salt thereof.--

--10. (Amended) 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-[3-(4-*n*-butyloxyphenyl)-2-methyl-2-propylamino]ethanol, or an acid addition salt thereof.--

--11. (Amended) The compound according to one of claims 1 to 6 or 8 to 10, wherein the acid addition salt thereof is formed with a pharmacologically acceptable acid.--

A2 Cont

--12. (Amended) A method of treating bronchial asthma, the inflammatory component in COPD, premature onset of labor in midwifery (tocolysis), atrio-ventricular block, bradycardiac hearth rhythm disorders, circulatory shock, or itching and inflammation of the skin in a host in need of such treatment, the method comprising administering to the host the compound according to one of claims 1 to 6 or 8 to 10.--

--13. (Amended) A pharmaceutical preparation comprising a compound according to one of claims 1 to 6 or 8 to 10 and a conventional excipient or carrier.--

A3

--16. (New) The compound according to claim 7, wherein the acid addition salt thereof is formed with a pharmacologically acceptable acid.--

--17. (New) A pharmaceutical preparation comprising a compound according claim 7 and a conventional excipient or carrier.--